Reviewing IceCure Medical (NASDAQ:ICCM) and Cannlabs (OTCMKTS:CANL)

IceCure Medical (NASDAQ:ICCM) and Cannlabs (OTCMKTS:CANL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for IceCure Medical and Cannlabs, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	2	0	2.25
Cannlabs	0	0	0	0	0.00

IceCure Medical presently has a consensus target price of $2.64, indicating a potential upside of 270.97%. Given IceCure Medical’s stronger consensus rating and higher possible upside, research analysts plainly believe IceCure Medical is more favorable than Cannlabs.

Institutional & Insider Ownership

0.6% of IceCure Medical shares are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares IceCure Medical and Cannlabs”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.29 million	14.83	-$15.32 million	($0.26)	-2.73
Cannlabs	N/A	N/A	N/A	N/A	N/A

Cannlabs has lower revenue, but higher earnings than IceCure Medical.

Profitability

This table compares IceCure Medical and Cannlabs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-513.95%	-243.68%	-123.94%
Cannlabs	N/A	N/A	N/A

Risk and Volatility

IceCure Medical has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Cannlabs has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.

Summary

IceCure Medical beats Cannlabs on 6 of the 10 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Cannlabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.